Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts

Working with cultured dermal fibroblasts derived from control individuals and patients with systemic sclerosis (SSc), we have examined the effects of protein kinase C-delta (PKC-delta) on type I collagen biosynthesis and steady-state levels of COL1A1 and COL3A1 mRNAs. Rottlerin, a specific inhibitor...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 108; no. 9; pp. 1395 - 1403
Main Authors Jimenez, S A, Gaidarova, S, Saitta, B, Sandorfi, N, Herrich, D J, Rosenbloom, J C, Kucich, U, Abrams, W R, Rosenbloom, J
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.11.2001
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Working with cultured dermal fibroblasts derived from control individuals and patients with systemic sclerosis (SSc), we have examined the effects of protein kinase C-delta (PKC-delta) on type I collagen biosynthesis and steady-state levels of COL1A1 and COL3A1 mRNAs. Rottlerin, a specific inhibitor of PKC-delta, exerted a powerful, dose-dependent inhibition of type I and type III collagen gene expression in normal and SSc cells. Optimal rottlerin concentrations caused a 70-90% inhibition of type I collagen production, a >80% reduction in COL1A1 mRNA, and a >70% reduction in COL3A1 mRNA in both cell types. In vitro nuclear transcription assays and transient transfections with COL1A1 promoter deletion constructs demonstrated that rottlerin profoundly reduced COL1A1 transcription and that this effect required a 129-bp promoter region encompassing nucleotides -804 to -675. This COL1A1 segment imparted rottlerin sensitivity to a heterologous promoter. Cotransfections of COL1A1 promoter constructs with a dominant-negative PKC-delta expression plasmid showed that suppression of this kinase silenced COL1A1 promoter activity. The results indicate that PKC-delta participates in the upregulation of collagen gene transcription in SSc and suggest that treatment with PKC-delta inhibitors could suppress fibrosis in this disease.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Address correspondence to: Sergio A. Jimenez, Thomas Jefferson University, Division of Rheumatology, 233 S. 10th Street, Room 509 BLSB, Philadelphia, Pennsylvania 19107-5541, USA. Phone: (215) 503-5042; Fax: (215) 923-4649; E-mail: Sergio.Jimenez@mail.tju.edu.
ISSN:0021-9738
DOI:10.1172/JCI12347